KR101908350B1 - 항균성 퀴놀린 유도체 - Google Patents

항균성 퀴놀린 유도체 Download PDF

Info

Publication number
KR101908350B1
KR101908350B1 KR1020157031291A KR20157031291A KR101908350B1 KR 101908350 B1 KR101908350 B1 KR 101908350B1 KR 1020157031291 A KR1020157031291 A KR 1020157031291A KR 20157031291 A KR20157031291 A KR 20157031291A KR 101908350 B1 KR101908350 B1 KR 101908350B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
het
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157031291A
Other languages
English (en)
Korean (ko)
Other versions
KR20150126737A (ko
Inventor
제롬 에밀 조르쥬 길레몽
이스멧 도랑쥬
마갈리 마들렌 시몬 모테
코엔라트 요제프 로데윅 마르셀 안드리스
아닐 코울
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37909392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101908350(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20150126737A publication Critical patent/KR20150126737A/ko
Application granted granted Critical
Publication of KR101908350B1 publication Critical patent/KR101908350B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1020157031291A 2006-12-06 2007-12-04 항균성 퀴놀린 유도체 Active KR101908350B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125510 2006-12-06
EP06125510.5 2006-12-06
PCT/EP2007/063314 WO2008068268A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097012242A Division KR101574642B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167037101A Division KR20170003741A (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Publications (2)

Publication Number Publication Date
KR20150126737A KR20150126737A (ko) 2015-11-12
KR101908350B1 true KR101908350B1 (ko) 2018-10-16

Family

ID=37909392

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157031291A Active KR101908350B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체
KR1020097012242A Active KR101574642B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체
KR1020167037101A Ceased KR20170003741A (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020097012242A Active KR101574642B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체
KR1020167037101A Ceased KR20170003741A (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Country Status (31)

Country Link
US (1) US8293732B2 (https=)
EP (1) EP2099760B1 (https=)
JP (1) JP5466012B2 (https=)
KR (3) KR101908350B1 (https=)
CN (1) CN101547905B (https=)
AP (1) AP2670A (https=)
AR (1) AR064147A1 (https=)
BR (1) BRPI0719939B8 (https=)
CA (1) CA2668517C (https=)
CL (1) CL2007003515A1 (https=)
CY (1) CY1114384T1 (https=)
DK (1) DK2099760T3 (https=)
EA (1) EA022344B1 (https=)
ES (1) ES2407824T3 (https=)
HR (1) HRP20130372T1 (https=)
IL (2) IL199078A (https=)
JO (1) JO2970B1 (https=)
ME (1) ME01521B (https=)
MX (1) MX2009005979A (https=)
MY (1) MY150411A (https=)
NO (1) NO342095B1 (https=)
NZ (1) NZ577128A (https=)
PL (1) PL2099760T3 (https=)
PT (1) PT2099760E (https=)
RS (1) RS52753B (https=)
SG (1) SG10201405650SA (https=)
SI (1) SI2099760T1 (https=)
TW (1) TWI396536B (https=)
UA (1) UA101306C2 (https=)
WO (1) WO2008068268A1 (https=)
ZA (1) ZA200903946B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CA2869453C (en) 2012-04-27 2021-03-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
ES2934785T3 (es) * 2016-03-07 2023-02-27 Global Alliance For Tb Drug Development Inc Compuestos antibacterianos y usos de los mismos
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006067048A1 (en) * 2004-12-24 2006-06-29 Janssen Pharmaceutica N.V. Quinoline derivatives for the treatment of latent tuberculosis
KR101553600B1 (ko) * 2006-12-06 2015-09-16 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
KR101574642B1 (ko) * 2006-12-06 2015-12-04 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EA011277B1 (ru) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
AP2188A (en) 2004-01-23 2010-12-14 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors.
EA011572B9 (ru) 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
RS56357B1 (sr) 2004-09-28 2017-12-29 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
AU2006263882B2 (en) 2005-06-28 2012-12-13 Janssen Pharmaceutica N.V Quinoline derivatives as antibacterial agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006067048A1 (en) * 2004-12-24 2006-06-29 Janssen Pharmaceutica N.V. Quinoline derivatives for the treatment of latent tuberculosis
KR101553600B1 (ko) * 2006-12-06 2015-09-16 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
KR101574642B1 (ko) * 2006-12-06 2015-12-04 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체

Also Published As

Publication number Publication date
CY1114384T1 (el) 2016-08-31
KR101574642B1 (ko) 2015-12-04
ME01521B (me) 2014-04-20
AP2009004871A0 (en) 2009-06-30
PT2099760E (pt) 2013-05-06
AR064147A1 (es) 2009-03-18
JO2970B1 (en) 2016-03-15
ES2407824T3 (es) 2013-06-14
KR20150126737A (ko) 2015-11-12
WO2008068268A1 (en) 2008-06-12
TW200838530A (en) 2008-10-01
MX2009005979A (es) 2009-06-16
MY150411A (en) 2014-01-15
DK2099760T3 (da) 2013-05-13
HRP20130372T1 (en) 2013-05-31
NZ577128A (en) 2012-01-12
CN101547905B (zh) 2015-01-28
IL199078A (en) 2015-10-29
SG10201405650SA (en) 2014-11-27
EA200970536A1 (ru) 2009-10-30
IL241548B (en) 2018-03-29
BRPI0719939B8 (pt) 2021-05-25
UA101306C2 (en) 2013-03-25
AP2670A (en) 2013-05-15
RS52753B (sr) 2013-08-30
HK1137433A1 (en) 2010-07-30
CL2007003515A1 (es) 2008-07-11
EP2099760B1 (en) 2013-02-20
KR20090090339A (ko) 2009-08-25
JP5466012B2 (ja) 2014-04-09
CA2668517C (en) 2016-01-12
IL241548A0 (en) 2015-11-30
JP2010511669A (ja) 2010-04-15
US20100029679A1 (en) 2010-02-04
TWI396536B (zh) 2013-05-21
BRPI0719939A2 (pt) 2014-03-11
CA2668517A1 (en) 2008-06-12
CN101547905A (zh) 2009-09-30
NO20092536L (no) 2009-08-24
PL2099760T3 (pl) 2013-07-31
SI2099760T1 (sl) 2013-06-28
BRPI0719939B1 (pt) 2020-11-17
NO342095B1 (no) 2018-03-19
ZA200903946B (en) 2010-08-25
EP2099760A1 (en) 2009-09-16
EA022344B1 (ru) 2015-12-30
AU2007328888A1 (en) 2008-06-12
KR20170003741A (ko) 2017-01-09
US8293732B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
KR101490222B1 (ko) 항균성 퀴놀린 유도체
KR101514992B1 (ko) 항균성 퀴놀린 유도체
KR102110355B1 (ko) 항균성 퀴놀린 유도체
KR101526175B1 (ko) 항박테리아 퀴놀린 유도체
KR101908350B1 (ko) 항균성 퀴놀린 유도체
KR101490221B1 (ko) 항박테리아 퀴놀린 유도체
KR101553600B1 (ko) 항균성 퀴놀린 유도체
JP5193858B2 (ja) 抗菌剤としてのキノリン誘導体
HK1137433B (en) Antibacterial quinoline derivatives
HK1208437B (zh) 抗菌的喹啉衍生物
HK1137435A (en) Antibacterial quinoline derivatives
HK1124232A1 (zh) 作为抗菌剂的喹啉衍生物
HK1137431B (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151030

Application number text: 1020097012242

Filing date: 20090612

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160201

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160202

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20160201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20161130

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160831

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180710

Appeal identifier: 2016101006792

Request date: 20161130

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161230

Application number text: 1020097012242

Filing date: 20090612

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20161230

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20161130

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20160401

Patent event code: PB09011R02I

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20170201

Patent event code: PE09021S02D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170824

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20180710

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20170106

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20181010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20181010

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20210915

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20210915

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220915

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220915

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230918

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 7

End annual number: 7